NCT03223025View on ClinicalTrials.gov

Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 9, 2016

Primary Completion Date

February 4, 2017

Study Completion Date

February 4, 2017

Conditions
Idiopathic Growth Hormone Deficiency
Interventions
DRUG

CinnaTropin®

0.03 mg/kg daily subcutaneous injections

DRUG

Nordilet®

0.03 mg/kg daily subcutaneous injections

Sponsors

Lead Sponsor

Cinnagen
All Listed Sponsors
lead

Cinnagen

INDUSTRY